InnovAge appoints Alice Raia as chief information officer » 08:1104/1404/14/21
InnovAge announced that…
InnovAge announced that it has appointed Alice Raia as chief information officer, bringing "significant expertise in developing technological strategies to improve customer engagement and drive meaningful improvements to patient outcomes," the company said. In this role, Raia will lead InnovAge's strategy and development for data management, digital technologies integration, information technologies and technical transformation. Raia brings to InnovAge more than 25 years of healthcare and technology experience, most recently as vice president - digital experience engineering at Kaiser Permanente in California.
|Over a week ago|
American Jobs Plan could strengthen backdrop for InnovAge, says Piper Sandler » 14:3804/0104/01/21
Piper Sandler analyst…
Piper Sandler analyst Chris Neamonitis believes the proposed American Jobs Plan, with likely support in the House, could strengthen the already-strong backdrop for InnovAge. While details remain light and the analyst doesn't see any immediate InnovAge impact, Neamonitis argues that the plan calls out a commitment to caregiving jobs and the easiest option for states would be to engage with InnovAge as a partner to grow HCBS via PACE, MFP. The analyst is a buyer of the stock on a strong runway that supports sustainable growth. He has an Overweight rating and a price target of $31 on the shares.
Former InnovAge employees express concerns over patient care, Capitol Forum says » 08:4903/3103/31/21
Former InnovAge employees…
Former InnovAge employees tell The Capitol Forum that the company enrolled patients with healthcare needs beyond its capabilities in order to collect payments under a federal program and increase revenue, the news service stated in a report available to its subscribers. Reference Link
Fly Intel: Top five analyst initiations » 09:5403/2903/29/21
INNV, OSCR, CTMX, FRO, CREE
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. InnovAge (INNV) initiated with a Buy at Goldman Sachs and Citi, initiated with an Overweight at Piper Sandler, initiated with an Equal Weight at Barclays and initiated with an Outperform at William Blair. 2. Oscar Health (OSCR) initiated with a Buy at Goldman Sachs, initiated with a Market Perform at Cowen, initiated with an Overweight at Morgan Stanley and initiated with a Buy at BofA. 3. CytomX Therapeutics (CTMX) initiated with an Overweight at JPMorgan. 4. Frontline (FRO) initiated with a Neutral at H.C. Wainwright. 5. Cree (CREE) initiated with a Buy at New Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
InnovAge initiated with an Outperform at William Blair » 07:1703/2903/29/21
William Blair analyst…
William Blair analyst Matt Larew initiated coverage of InnovAge with an Outperform rating and no price target. With a focus on high-cost, high-risk dual eligible patients, InnovAge stands to benefit from accelerating underlying demographic demand in the elderly population and continued adoption of capitated care delivery models to manage chronic conditions safely and effectively in the home and community, Larew tells investors in a research note. The analyst sees a "clear roadmap" to 20%-plus long-term growth.
InnovAge initiated with an Equal Weight at Barclays » 06:3403/2903/29/21
Barclays analyst Steve…
Barclays analyst Steve Valiquette initiated coverage of InnovAge with an Equal Weight rating.
InnovAge initiated with a Buy at Citi » 06:2503/2903/29/21
Citi analyst Ralph…
Citi analyst Ralph Giacobbe initiated coverage of InnovAge with a Buy rating and $30 price target. The company is a provider-based entity treating and managing care for high-cost, frail, and elderly individuals in a capitated value-based care model, Giacobbe tells investors in a research note. The analyst sees "significant opportunities for growth" via InnovAge's existing centers and through de novo, acquisitions and geographic expansion.
InnovAge initiated with a Buy at Goldman Sachs » 04:5703/2903/29/21
Goldman Sachs analyst…
Goldman Sachs analyst Jamie Perse initiated coverage of InnovAge with a Buy rating and $32 price target. The analyst views the company as a "unique value-based care asset" that is well positioned in a relatively small but growing end-market, with limited direct competition. The program of all-inclusive care for the elderly market in which InnovAge participates is still "significantly underpenetrated" at just 3% of total addressable market, with opportunities for market expansion in both current and future geographies, Perse tells investors in a research note.
InnovAge initiated with an Overweight at Piper Sandler » 04:5303/2903/29/21
Piper Sandler analyst…
Piper Sandler analyst Chris Neamonitis initiated coverage of InnovAge with an Overweight rating and $31 price target. InnovAge represents an "aligned integration" of Medicare and Medicaid resources, and has embraced being a "payvider" long before trend emergence, Neamonitis tells investors in a research note. The analyst sees "meaningful opportunity" for InnovAge to broaden the scope of the populations that it serves.
|Over a month ago|
Opening Day: InnovAge rises, Oscar Health slips on first trading day » 09:1403/0703/07/21
INNV, OSCR, VPCC, VPCB, WPCA, ATVC, WPCB, DMYQ, TWNT, FRSG, IPVI, IPVF, IPVA, PSAGU, KVSA, AURC, ATAQ, TRCA, ISOS, MACC, ROCR, DHBC, GBRG, TSPQ, FTEV, SNII, OPHA, NDAC, ANZU, NSTD, NSTC, LOKM, AMPI, COIN, RBLX, VZIO, GROY, ALHC, HOOD, PLTR, ASAN, WORK, SPOT, BABA